Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01769274 · ClinicalTrials.gov registry record · Phase 2
Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia
A Phase 2 study of Inherited Erythromelalgia, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT01769274: Completed Phase 2 study of Inherited Erythromelalgia, sponsored by Pfizer.
NCT01769274 is a Phase 2 study of Inherited Erythromelalgia that has completed, run by Pfizer. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01769274, a Phase 2 study of Inherited Erythromelalgia, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the efficacy and safety of single doses of PF-05089771 against placebo in treatment of pain in patients with primary, inherited erythromelalgia.
Primary Outcome
Participants rated severity of their pain at 11 point PI-NRS, by choosing a number between 0 and 10, where 0= no pain and 10= worst possible pain; higher scores signify more pain. The average pain score was calculated as the mean of the pain scores recorded every 15 minutes from 0 to 4 hours post-dose.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PF-05089771
Study Locations (1)
Connecticut
- New Haven Clinical Research Unit - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-10-22 |
| Est. Completion | 2013-07-12 |
| Phase | Phase 2 |
What the finished NCT01769274 record still lists
NCT01769274 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Inherited Erythromelalgia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01769274 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT01769274 about?
NCT01769274 is a clinical study titled "Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia". The purpose of this study is to evaluate the efficacy and safety of single doses of PF-05089771 against placebo in treatment of pain in patients with primary, inherited erythromelalgia.
What is the current status of trial NCT01769274?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2012-10-22. Estimated completion is 2013-07-12.
What conditions does trial NCT01769274 study?
This clinical trial studies the following conditions: Inherited Erythromelalgia.
What interventions are being tested in trial NCT01769274?
The interventions under investigation include: Placebo (DRUG), PF-05089771 (DRUG).
Who is sponsoring clinical trial NCT01769274?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01769274 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01769274's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI